ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 220 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $221,000 | -11.2% | 3,048 | +3.0% | 0.00% | – |
| Q4 2021 | $249,000 | +1.2% | 2,958 | +8.4% | 0.00% | – |
| Q3 2021 | $246,000 | -70.5% | 2,729 | -68.8% | 0.00% | -100.0% |
| Q2 2021 | $833,000 | -94.9% | 8,734 | -93.9% | 0.00% | -91.7% |
| Q1 2021 | $16,383,000 | -21.4% | 143,890 | -4.5% | 0.01% | -25.0% |
| Q4 2020 | $20,848,000 | +64.9% | 150,605 | -2.1% | 0.02% | +45.5% |
| Q3 2020 | $12,639,000 | -5.9% | 153,781 | -10.4% | 0.01% | -15.4% |
| Q2 2020 | $13,429,000 | +173.4% | 171,687 | +55.3% | 0.01% | +116.7% |
| Q1 2020 | $4,911,000 | +6.6% | 110,529 | +2.4% | 0.01% | +50.0% |
| Q4 2019 | $4,609,000 | +63.6% | 107,911 | +63.9% | 0.00% | +33.3% |
| Q3 2019 | $2,817,000 | -29.5% | 65,842 | +4.7% | 0.00% | -25.0% |
| Q2 2019 | $3,994,000 | +6.8% | 62,895 | +16.7% | 0.00% | 0.0% |
| Q1 2019 | $3,740,000 | +47.9% | 53,915 | -7.3% | 0.00% | +33.3% |
| Q4 2018 | $2,528,000 | -40.4% | 58,153 | +4.7% | 0.00% | -25.0% |
| Q3 2018 | $4,242,000 | -1.4% | 55,565 | -0.7% | 0.00% | 0.0% |
| Q2 2018 | $4,303,000 | +129.9% | 55,975 | +52.4% | 0.00% | +100.0% |
| Q1 2018 | $1,872,000 | +13.0% | 36,720 | +2.8% | 0.00% | 0.0% |
| Q4 2017 | $1,657,000 | +3.8% | 35,723 | +19.2% | 0.00% | 0.0% |
| Q3 2017 | $1,596,000 | -16.0% | 29,971 | -2.1% | 0.00% | 0.0% |
| Q2 2017 | $1,901,000 | -18.6% | 30,604 | -11.1% | 0.00% | 0.0% |
| Q1 2017 | $2,335,000 | -4.0% | 34,443 | -0.4% | 0.00% | -33.3% |
| Q4 2016 | $2,432,000 | -18.9% | 34,589 | -18.1% | 0.00% | 0.0% |
| Q3 2016 | $2,998,000 | +47.5% | 42,259 | +1.7% | 0.00% | +50.0% |
| Q2 2016 | $2,033,000 | -14.8% | 41,566 | +10.3% | 0.00% | -33.3% |
| Q1 2016 | $2,386,000 | -45.7% | 37,692 | -3.7% | 0.00% | -40.0% |
| Q4 2015 | $4,393,000 | +33.3% | 39,156 | +14.4% | 0.01% | +25.0% |
| Q3 2015 | $3,295,000 | +58.9% | 34,213 | +69.0% | 0.00% | +100.0% |
| Q2 2015 | $2,073,000 | – | 20,243 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |